Eric J Small

Eric J Small

UNVERIFIED PROFILE

Are you Eric J Small?   Register this Author

Register author
Eric J Small

Eric J Small

Publications by authors named "Eric J Small"

Are you Eric J Small?   Register this Author

100Publications

3619Reads

41Profile Views

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Prostate Cancer Prostatic Dis 2020 Mar 3;23(1):66-73. Epub 2019 May 3.

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0152-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825875PMC
March 2020

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.

Eur Urol 2020 Mar 20;77(3):333-341. Epub 2019 Oct 20.

Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.09.036DOI Listing
March 2020

Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer.

Clin Genitourin Cancer 2019 Nov 6. Epub 2019 Nov 6.

Division of Hematology and Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.10.030DOI Listing
November 2019

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.

Clin Cancer Res 2019 Jul 22;25(14):4290-4299. Epub 2019 Apr 22.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0404DOI Listing
July 2019

Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.

Future Oncol 2019 Jul 11;15(20):2337-2348. Epub 2019 Jun 11.

Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0021DOI Listing
July 2019

Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT.

Clin Nucl Med 2019 May;44(5):e367-e369

From the Division of Nuclear Medicine, Department of Radiology and Biomedical Imaging.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002507DOI Listing
May 2019

Germline and Somatic Mutations in Prostate Cancer for the Clinician.

J Natl Compr Canc Netw 2019 May;17(5):515-521

aDivision of Medical Oncology, University of Washington, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.7307DOI Listing
May 2019

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

Clin Genitourin Cancer 2019 Feb 24;17(1):e92-e96. Epub 2018 Sep 24.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.013DOI Listing
February 2019

Apalutamide and its use in the treatment of prostate cancer.

Future Oncol 2019 Feb 14;15(6):591-599. Epub 2018 Nov 14.

Division of Hematology/Oncology, Department of Medicine, University of California at San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0546
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391625PMC
February 2019

Reply to A. Dalla Volta et al.

J Clin Oncol 2019 02 17;37(4):351-352. Epub 2018 Dec 17.

Rahul Aggarwal, MD, University of California San Francisco, San Francisco, CA; Jiaoti Huang, MD, PhD, Duke University, Durham, NC; Joshi Alumkal, MD, Oregon Health Sciences University, Portland, OR; Felix Y. Feng, MD and Li Zhang, PhD, University of California San Francisco, San Francisco, CA; Joshua M. Stuart, PhD, University of California Santa Cruz, Santa Cruz, CA; and Eric J. Small, MD, University of California San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01487DOI Listing
February 2019

Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases.

Clin Nucl Med 2019 Jan;44(1):e28-e32

From the Departments of Radiology and Biomedical Imaging.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002367DOI Listing
January 2019

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.

Ther Adv Urol 2018 Dec 11;10(12):445-454. Epub 2018 Nov 11.

Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1756287218811450
Publisher Site
http://dx.doi.org/10.1177/1756287218811450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295778PMC
December 2018

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

J Clin Oncol 2018 08 9;36(24):2492-2503. Epub 2018 Jul 9.

Rahul Aggarwal, Li Zhang, Felix Y. Feng, Paul Lloyd, Jack Youngren, Adam Foye, Denise Playdle, Charles J. Ryan, and Eric J. Small, University of California San Francisco, San Francisco; Alana S. Weinstein, Verena Friedl, Can Zhang, Christopher K. Wong, Vlado Uzunangelov, Artem Sokolov, Yulia Newton, and Joshua M. Stuart, University of California Santa Cruz, Santa Cruz; Owen N. Witte and Matthew Rettig, University of California Los Angeles, Los Angeles; Christopher P. Evans and Primo Lara, University of California Davis, Davis, CA; Jiaoti Huang, Duke University, Durham, NC; Joshi J. Alumkal, George V. Thomas, and Tomasz M. Beer, Oregon Health Sciences University, Portland, OR; Martin Gleave and Kim N. Chi, University of British Columbia, Vancouver, British Columbia, Canada; Lawrence True, University of Washington, Seattle, WA; Himisha Beltran and Mark A. Rubin, Weill Cornell Medicine, New York, NY; and Francesca Demichelis, University of Trento, Trento, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6880DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366813PMC
August 2018

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Cell 2018 07 19;174(3):758-769.e9. Epub 2018 Jul 19.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA; Division of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA; Department of Radiation Oncology, UCSF, San Francisco, CA, USA; Department of Urology, UCSF, San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2018.06.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425931PMC
July 2018

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Clin Genitourin Cancer 2018 06 27;16(3):184-190.e2. Epub 2017 Dec 27.

Division of Hematology/Oncology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.12.004DOI Listing
June 2018

Apalutamide and Metastasis-free Survival in Prostate Cancer.

N Engl J Med 2018 06;378(26):2542

University of California San Francisco, San Francisco, CA

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1806189
Publisher Site
http://dx.doi.org/10.1056/NEJMc1806189DOI Listing
June 2018

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

Eur Urol Oncol 2018 05 15;1(1):78-82. Epub 2018 May 15.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.03.010DOI Listing
May 2018

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

N Engl J Med 2018 Apr 8;378(15):1408-1418. Epub 2018 Feb 8.

From the Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (M.R.S.); Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal (F.S.); Guy's, King's and St. Thomas' Hospitals, Great Maze Pond, London (S.C.); Georges Pompidou Hospital, Paris (S.O.); University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany (B.A.H.); Veterans Affairs Portland Health Care System, Portland, and Knight Cancer Institute, Oregon Health and Science University, Portland (J.N.G.); Spanish National Cancer Research Center, Madrid, and Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Malaga, Malaga - both in Spain (D.O.); Centre for Personalised Nanomedicine, University of Queensland, Brisbane, Australia (P.N.M.); St. Mary's Hospital of Catholic University, Seoul, South Korea (J.Y.L.); Yokohama City University Medical Center, Yokohama, Japan (H.U.); Janssen Research and Development, Los Angeles (A.L.-G., G.C.T., B.M.E., Y.S., Y.C.P., W.R.R., M.K.Y.); and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco (E.J.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1715546DOI Listing
April 2018

Impact of Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.

J Nucl Med 2017 12 18;58(12):1956-1961. Epub 2017 May 18.

UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.117.192
Publisher Site
http://dx.doi.org/10.2967/jnumed.117.192476DOI Listing
December 2017

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

J Natl Cancer Inst 2017 Dec;109(12)

Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Institute of Biosciences and Medical Technology, University of Tampere, Tampere, Finland; Department of Medicine and Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Oregon Health and Science University (OHSU) Knight Cancer Institute, Portland, OR; Department of Urology, University of California, Davis, School of Medicine, Sacremento, CA; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440274PMC
December 2017

Optimal MRI sequences for Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer.

EJNMMI Res 2017 Sep 19;7(1):77. Epub 2017 Sep 19.

Department of Radiology and Biomedical Imaging, University of California, 505 Parnassus Avenue - 0628, San Francisco, CA, 94143-0628, USA.

View Article

Download full-text PDF

Source
http://ejnmmires.springeropen.com/articles/10.1186/s13550-01
Publisher Site
http://dx.doi.org/10.1186/s13550-017-0327-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605480PMC
September 2017

CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.

J Vasc Interv Radiol 2017 Aug 24;28(8):1073-1081.e1. Epub 2017 May 24.

Department of Radiology and Biomedical Imaging, University of California, San Francisco, 513 Parnassus Avenue, S-261, San Francisco, CA 94143-0628.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2017.04.019DOI Listing
August 2017

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.

Eur Urol 2017 07 1;72(1):34-42. Epub 2017 Mar 1.

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.02.023DOI Listing
July 2017

Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.

Expert Rev Anticancer Ther 2017 07 31;17(7):625-633. Epub 2017 May 31.

a Department of Medicine , University of California, San Francisco , San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1333903DOI Listing
July 2017

Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.

Authors:
Eric J Small

Cancer Cell 2017 07;32(1):6-8

University of California, San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.06.007DOI Listing
July 2017

Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making.

JCO Precis Oncol 2017 28;1. Epub 2017 Jun 28.

Derrick L. Tao, Shawna Bailey, Tomasz M. Beer, Erik Foss, Brooke Beckett, Alice Fung, Bryan R. Foster, Alexander Guimaraes, Jeremy P. Cetnar, Julie N. Graff, Kristine M. Eilers, Christopher L. Corless, George V. Thomas, and Joshi J. Alumkal, Oregon Health & Science University, Portland, OR; and Eric J. Small, University of California, San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.16.00067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812573PMC
June 2017

Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.

Oncology (Williston Park) 2017 06;31(6):467-74

View Article

Download full-text PDF

Source
June 2017

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

J Clin Oncol 2017 02 14;35(6):591-597. Epub 2016 Nov 14.

Toni K. Choueiri and Meghara K. Walsh, Dana-Farber Cancer Institute; M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben L. Sanford, Alliance Statistics and Data Center and Duke University; Daniel J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Olwen Hahn, Alliance Protocol Operations Office, Chicago, IL; Darren R. Feldman and Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University Medical Center, Columbus, OH; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Eric J. Small, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; and Shaker Dakhil, University of Kansas Wichita, Wichita, KS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455807PMC
February 2017

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

J Nucl Med 2017 Jan 22;58(1):81-84. Epub 2016 Sep 22.

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.116.181800DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209643PMC
January 2017

A Feasibility Study Showing [Ga]Citrate PET Detects Prostate Cancer.

Mol Imaging Biol 2016 12;18(6):946-951

Department of Radiology and Biomedical Imaging, University of California, 185 Berry Street, Lobby 6, Suite 350, San Francisco, CA, 94107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-016-0966-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430569PMC
December 2016

Prospects for the use of ipilimumab in treating advanced prostate cancer.

Expert Opin Biol Ther 2016 25;16(3):421-32. Epub 2016 Jan 25.

a Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center , University of California, San Francisco , San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2016.1136284DOI Listing
October 2016

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.

Cancer Lett 2016 09 22;380(1):144-52. Epub 2016 Jun 22.

Department of Urology, University of California, San Francisco (UCSF), San Francisco, CA, USA; Division of Hematology & Oncology, University of California, San Francisco (UCSF), San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2016.06.017DOI Listing
September 2016

Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.

Expert Rev Vaccines 2015 21;14(12):1529-41. Epub 2015 Oct 21.

a UCSF Helen Diller Family Comprehensive Cancer Center , University of California, San Francisco , San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14760584.2015.1099437DOI Listing
August 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

Can J Urol 2015 Dec;22(6):8048-55

University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
December 2015

Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients.

Contemp Clin Trials 2015 Nov 3;45(Pt B):443-448. Epub 2015 Oct 3.

Helen Diller Family Comprehensive Cancer Center,University of CaliforniaSan Francisco, USA; Department of Medicine, Division of Hematology and Oncology,University of CaliforniaSan Francisco, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2015.09.023DOI Listing
November 2015

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).

EBioMedicine 2015 Nov 8;2(11):1814-20. Epub 2015 Sep 8.

Department of Biostatistics and Bioinformatics, and Alliance Statistics and Data Center, Duke University, Durham, NC, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.09.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740313PMC
November 2015

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.

Cancer Immunol Res 2015 Sep 12;3(9):1008-16. Epub 2015 May 12.

Division of Hematology/Oncology, University of California, San Francisco, California. UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561203PMC
September 2015

Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?

Cancer 2015 Jun 11;121(11):1906. Epub 2015 Feb 11.

Department of Urology, University of California at San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29252DOI Listing
June 2015

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Clin Cancer Res 2015 May 23;21(10):2315-24. Epub 2015 Feb 23.

Vancouver Prostate Centre, Vancouver, British Columbia, Canada. Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2666DOI Listing
May 2015

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

J Clin Oncol 2015 Apr 26;33(12):1356-63. Epub 2015 Jan 26.

Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.3875DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881370PMC
April 2015

Reply to F. Valcamonico et al.

J Clin Oncol 2014 Nov 15;32(32):3685. Epub 2014 Sep 15.

University of California, San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3808DOI Listing
November 2014

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

J Natl Cancer Inst 2014 Nov 24;106(11). Epub 2014 Sep 24.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (LF, PC, VW, SC, JL, JS, EJS); Virginia Mason Medical Center, Seattle, WA (JC); Oregon Health & Science University, Portland, OR (CLA); University of Utah School of Medicine, Salt Lake City, UT (RAS); Dendreon Corporation, Seattle, WA (NAS, RBS, MWF).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241888PMC
November 2014

Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die?

Authors:
Eric J Small

J Clin Oncol 2014 Nov 13;32(33):3689-91. Epub 2014 Oct 13.

University of California, San Francisco, San Francisco, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.8534DOI Listing
November 2014

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

Clin Genitourin Cancer 2014 Oct 28;12(5):e167-72. Epub 2014 Mar 28.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.03.010DOI Listing
October 2014

Small-cell/neuroendocrine prostate cancer: a growing threat?

Oncology (Williston Park) 2014 Oct;28(10):838-40

View Article

Download full-text PDF

Source
October 2014

Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.

J Natl Compr Canc Netw 2014 May;12(5):719-26

From the aDepartment of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, and Department of Medicine, and bDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0073DOI Listing
May 2014

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

J Clin Oncol 2014 Apr 3;32(11):1143-50. Epub 2014 Mar 3.

Matthew R. Smith and Philip Saylor, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben Sanford, Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC; Charles J. Ryan and Eric J. Small, University of California at San Francisco, San Francisco, CA; Walter Stadler, University of Chicago; Nirmala Bhoopalam, Loyola University of Chicago, Chicago, IL; Arif Hussain, University of Maryland, Baltimore, MD; Nicholas Vogelzang, Nevada Cancer Research Foundation CCOP, Las Vegas, NV; Ralph J. Hauke, University of Nebraska, Omaha, NE; J. Paul Monk, Ohio State University, Columbus, OH; W. Kevin Kelly, Thomas Jefferson University, Philadelphia, PA; Michael Morris, Memorial Sloan-Kettering Cancer Center, New York, NY; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.6500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970172PMC
April 2014

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

J Clin Oncol 2014 Mar 21;32(7):671-7. Epub 2014 Jan 21.

Susan Halabi, Chen-Yen Lin, and Ellen B. Kaplan, Duke University; Judd W. Moul, Duke Cancer Institute, Durham, NC; W. Kevin Kelly, Thomas Jefferson University, Philadelphia, PA; Karim S. Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Michael J. Morris, Memorial Sloan-Kettering Cancer Center, New York, NY; and Eric J. Small, University of California, San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.3696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927736PMC
March 2014

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Cancer 2014 Jan 8;120(1):52-60. Epub 2013 Oct 8.

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina; Alliance Statistical and Data Center, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.28221
Publisher Site
http://dx.doi.org/10.1002/cncr.28221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869105PMC
January 2014

Prostate cancer, version 1.2014.

J Natl Compr Canc Netw 2013 Dec;11(12):1471-9

From 1Roswell Park Cancer Institute; 2Dana-Farber/Brigham and Women's Cancer Center; 3Duke Cancer Institute; 4The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 5Huntsman Cancer Institute at the University of Utah; 6Memorial Sloan-Kettering Cancer Center; 7Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 8Prostate Health Education Network; 9University of Washington/Seattle Cancer Care Alliance; 10Fox Chase Cancer Center; 11City of Hope Comprehensive Cancer Center; 12Massachusetts General Hospital Cancer Center; 13Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 14Vanderbilt-Ingram Cancer Center; 15University of Michigan Comprehensive Cancer Center; 16Moffitt Cancer Center; 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The University of Texas MD Anderson Cancer Center; 20Patient Advocate; 21Stanford Cancer Institute; 22Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and 24National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0174DOI Listing
December 2013